Treatments for<unk> s include blocking the synthesis or action of the hormone or surgery to remove the organ that produces the hormone. Androgen deprivation therapy includes treatment with androgen receptor antagonists and/or surgical removal of the testes while estrogen deprivation therapy involves treatment with estrogen receptor antagonists and/or surgical removal of the ovaries. Receptor antagonists Antiandrogens or antiestrogen are used to block the binding of androgen and estrogen to their respective nuclear hormone receptors and thereby blocks the proliferative effects of these hormone on hormone dependent<unk> . For example, the antiestrogen tamoxifen used for the treatment of breast<unk>  while the antiandrogen bicalutamide alone or in combination with castration is used to treat prostate<unk> . Interruption of hormonal stimulus. For example, tamoxifen can slow the progression until actual hormone independence occurs in the pathway later. In more recent years, evidence in support of this cell proliferation model of hormone responsive<unk>  etiology has continued to accumulate. Anti-hormone therapies are proved to be effective in stopping progression and thereby increasing the time to recurrence or death. Receptor agonists Progesterone is regarded as the major endometrial tumor suppressor, Synthesis inhibitors Various agents that block key events in the synthesis of hormones are sometimes used to treat hormone dependent<unk> s. Aromatase inhibitors such as anastrozole block the synthesis of estrogen while CYP17A1 inhibitors such as abiraterone block the synthesis of androgen. Gonadotropin-releasing hormone antagonists blocks the signaling that stimulates androgen synthesis. Surgery As the growth of hormone dependent<unk>  is driven by sex hormones, surgical removal of the organs that synthesizes the sex hormone is sometimes performed. In the case of prostate<unk> , orchiectomy (surgical castration) of the testes is sometimes performed while oophorectomy (surgical removal of the ovaries) is sometimes performed to prevent breast<unk>  in high risk women with BRCA1 or BRCA2 mutations.
Hormone-sensitive cancer
Hormone receptor positive breast tumor
Rapid hormone cycling
Antiestrogen withdrawal response
Endocrine therapy resistance in breast cancer
Biochemical recurrence
Menopause
Side effects of bicalutamide